Related Experiment Video

Updated: May 8, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Targeting the calmodulin-regulated ErbB/Grb7 signaling axis in cancer therapy

Antonio Villalobo1, Irene García-Palmero, Silviya R Stateva

  • 1Instituto de Investigaciones Biomédicas, Consejo Superior de Investigaciones Científicas & Universidad Autónoma de Madrid. antonio.villalobo@iib.uam.es

Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques
|August 21, 2013
PubMed

Insights

Calmodulin (CaM) regulates ErbB receptor and Grb7 signaling pathways crucial for cancer cell survival. Targeting CaM or its binding sites on these proteins offers potential anti-cancer therapies.

Area of Science:

  • Molecular Biology
  • Cancer Signaling
  • Pharmacological Intervention

Background:

  • Aberrantly expressed signal transduction pathways are key targets in cancer therapy.
  • Calmodulin (CaM) is a calcium-binding protein regulating essential cellular processes.
  • ErbB receptors (EGFR/ErbB1, ErbB2) and Grb7 are critical in cell survival and cancer signaling.

Purpose of the Study:

  • To review CaM's regulation of ErbB receptor and Grb7 signaling pathways.
  • To discuss current strategies for inhibiting hyperactivity of ErbB/Grb7 in tumors.
  • To analyze targeting CaM-binding sites for anti-cancer therapy.

Main Methods:

  • Literature review of signaling mechanisms and CaM regulation.
  • Analysis of current therapeutic efforts targeting ErbB receptors and Grb7.
  • Evaluation of strategies for targeting CaM or its binding domains.

Main Results:

  • CaM exerts regulatory control over the ErbB/Grb7 signaling axis.
  • Hyperactivity of ErbB receptors and Grb7 is implicated in tumor progression.
  • Targeting CaM-binding sites presents a potential therapeutic avenue.

Conclusions:

  • CaM plays a significant role in ErbB/Grb7-mediated cancer cell signaling.
  • Directly targeting CaM or its binding domains on ErbB/Grb7 are viable anti-cancer strategies.
  • Further analysis of pros and cons is needed for optimal therapeutic development.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...